A Treatment Study Protocol for Participants 1-45 Years With Acute Lymphoblastic Leukaemia

NCT04307576

Last updated date
Study Location
L'hôpital Universitaire des enfants Reine Fabiola (Huderf)
Brussels, , 1020, Belgium
Contact
+46 8 524 800 00

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

+46 8 524 800 00

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Acute Lymphoblastic Leukemia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
1-45 year
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients newly diagnosed with T-lymphoblastic (T-cell) or B-lymphoblastic precursor (BCP) leukaemia (ALL) according to the WHO-classification of Tumours of Haematopoetic and Lymphoid Tissues (Revised 4th edition 2017) and with a diagnosis confirmed by an accredited laboratory at a participating paediatric oncology or adult haematology centre.

- Age ≥ 365 days and < 46 years (one day before 46th birthday) at the time of diagnosis.

- Informed consent signed by the patient and/or parents/legal guardians according to country-specific age-related guidelines (http://www.ema.europa.eu/docs/en_GB/document_library/Other/2015/12/WC500199234.pdf ).

- The ALL diagnosis should be confirmed by an accredited laboratory at a participating paediatric oncology or adult haematology centre.

- The patient should be diagnosed and treated at a participating paediatric oncology or adult haematology centre in the participating countries.

- The patient should be a resident in one of the participating countries on a permanent basis or should intend to settle in a participating country, for instance by an application for asylum. Patients who are visiting the country as tourists should not be included. However, returning expatriots with primary diagnosis abroad may be included if no treatment has been administered and the diagnostic procedures are repeated at a participating centre.

- All women of childbearing potential (WOCBP) have to have a negative pregnancy test within 2 weeks prior to the start of treatment.

- For each intervention/randomisation an additional set of inclusion-criteria is provided.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Age < 365 days at diagnosis (infant ALL) or >45 years at diagnosis.


- Patients with a previous malignant diagnosis (ALL as a second malignant neoplasm -
SMN).


- Relapse of ALL.


- Patients with mature B-ALL (as defined by Surface Ig positivity or documented presence
of one of the t(8;14), t(2;8), t(8;22) translocations and breakpoint as in B-ALL).


- Patients with Ph-positive ALL (documented presence of t(9;22)(q34;q11) and/or of the
BCR/ABL fusion transcript). These patients will be transferred to an adequate trial
for t(9;22) if available.


- ALL prone syndromes (e.g. Li-Fraumeni syndrome, germline ETV6 mutation), except for
Down syndrome. Exploration for such ALL prone syndromes is not mandatory.


- Treatment with systemic corticosteroids (>10mg/m2/day) for more than one week and/or
other chemotherapeutic agents in a 4-week interval prior to diagnosis (pre-treatment).


- Pre-existing contraindications to any treatment according to the ALLTogether protocol
(constitutional or acquired disease prior to the diagnosis of ALL preventing adequate
treatment).


- Any other disease or condition, as determined by the investigator, which could
interfere with the participation in the study according to the study protocol, or with
the ability of the patients to cooperate and comply with the study procedures.


- Women of childbearing potential who are pregnant at the time of diagnosis.


- Women of childbearing potential and fertile men who are sexually active and are
unwilling to use adequate contraception during therapy. Efficient birth control is
required.


- Female patients, who are breast-feeding.


- Essential data missing from the registration of characteristics at diagnosis (in
consultation with the protocol chair).


- For each intervention/randomisation an additional set of exclusion-criteria is
provided.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Acute Lymphoblastic LeukemiaInotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia
NCT03913559
  1. Memphis, Tennessee
ALL GENDERS
0+
years
MULTIPLE SITES
Acute Lymphoblastic LeukemiaCMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)
NCT01134575
  1. Houston, Texas
ALL GENDERS
16 Years+
years
MULTIPLE SITES
Acute Lymphoblastic LeukemiaA Treatment Study Protocol for Participants 1-45 Years With Acute Lymphoblastic Leukaemia
NCT04307576
  1. Brussels,
  2. Brussels,
  3. Brussels,
  4. Edegem,
  5. Ghent,
  6. Leuven,
  7. Leuven,
  8. Liège,
  9. Liège,
  10. Aalborg,
  11. Aarhus,
  12. Aarhus,
  13. Copenhagen,
  14. Copenhagen,
  15. Odense,
  16. Tallinn,
  17. Tallinn,
  18. Tartu,
  19. Tartu,
  20. Helsinki,
  21. Helsinki,
  22. Kuopio,
  23. Kuopio,
  24. Oulu,
  25. Oulu,
  26. Tampere,
  27. Tampere,
  28. Turku,
  29. Turku,
  30. Bielefeld,
  31. Bonn,
  32. Bremen,
  33. Hamburg,
  34. Krefeld,
  35. Mainz,
  36. München,
  37. Reykjavík,
  38. Dublin,
  39. Vilnius,
  40. Utrecht,
  41. Bergen,
  42. Bergen,
  43. Oslo,
  44. Oslo,
  45. Stavanger,
  46. Tromsø,
  47. Tromsø,
  48. Trondheim,
  49. Trondheim,
  50. Coimbra,
  51. Lisboa,
  52. Porto,
  53. Gothenburg,
  54. Gothenburg,
  55. Linköping,
  56. Linköping,
  57. Lund,
  58. Lund,
  59. Stockholm,
  60. Stockholm,
  61. Umeå,
  62. Umeå,
  63. Uppsala,
  64. Uppsala,
  65. Örebro,
  66. Aberdeen,
  67. Aberdeen,
  68. Belfast,
  69. Belfast,
  70. Birmingham,
  71. Birmingham,
  72. Bristol,
  73. Cambridge,
  74. Cardiff,
  75. Cardiff,
  76. Dundee,
  77. Edinburgh,
  78. Edinburgh,
  79. Glasgow,
  80. Glasgow,
  81. Leeds,
  82. Leeds,
  83. Leicester,
  84. Liverpool,
  85. Liverpool,
  86. London,
  87. London,
  88. Manchester,
  89. Manchester,
  90. Newcastle,
  91. Newcastle,
  92. Nottingham,
  93. Nottingham,
  94. Oxford,
  95. Oxford,
  96. Plymouth,
  97. Sheffield,
  98. Sheffield,
  99. Southampton,
  100. Stoke,
  101. Sutton,
ALL GENDERS
1 Year+
years
MULTIPLE SITES
Acute Lymphoblastic LeukemiaA Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia
NCT01564784
  1. La Jolla, California
  2. La Jolla, California
  3. La Jolla, California
  4. Los Angeles, California
  5. Los Angeles, California
  6. Los Angeles, California
  7. Los Angeles, California
  8. Los Angeles, California
  9. Los Angeles, California
  10. Los Angeles, California
  11. Los Angeles, California
  12. Los Angeles, California
  13. Los Angeles, California
  14. Orange, California
  15. Orange, California
  16. Orange, California
  17. Palo Alto, California
  18. San Diego, California
  19. Stanford, California
  20. Stanford, California
  21. Stanford, California
  22. Aurora, Colorado
  23. Aurora, Colorado
  24. Aurora, Colorado
  25. New Haven, Connecticut
  26. Miami, Florida
  27. Orlando, Florida
  28. Orlando, Florida
  29. Orlando, Florida
  30. Orlando, Florida
  31. Atlanta, Georgia
  32. Atlanta, Georgia
  33. Atlanta, Georgia
  34. Atlanta, Georgia
  35. Atlanta, Georgia
  36. Atlanta, Georgia
  37. Augusta, Georgia
  38. Augusta, Georgia
  39. Chicago, Illinois
  40. Chicago, Illinois
  41. Chicago, Illinois
  42. Chicago, Illinois
  43. Chicago, Illinois
  44. Iowa City, Iowa
  45. Kansas City, Kansas
  46. Westwood, Kansas
  47. Louisville, Kentucky
  48. Louisville, Kentucky
  49. Baltimore, Maryland
  50. Baltimore, Maryland
  51. Baltimore, Maryland
  52. Boston, Massachusetts
  53. Boston, Massachusetts
  54. Boston, Massachusetts
  55. Ann Arbor, Michigan
  56. Detroit, Michigan
  57. Farmington Hills, Michigan
  58. Hackensack, New Jersey
  59. Hackensack, New Jersey
  60. New Brunswick, New Jersey
  61. Albuquerque, New Mexico
  62. Albuquerque, New Mexico
  63. Lake Success, New York
  64. Manhasset, New York
  65. New York, New York
  66. New York, New York
  67. New York, New York
  68. Rochester, New York
  69. Stony Brook, New York
  70. Stony Brook, New York
  71. Stony Brook, New York
  72. Stony Brook, New York
  73. Chapel Hill, North Carolina
  74. Chapel Hill, North Carolina
  75. Winston-Salem, North Carolina
  76. Cincinnati, Ohio
  77. Cleveland, Ohio
  78. Cleveland, Ohio
  79. Oklahoma City, Oklahoma
  80. Oklahoma City, Oklahoma
  81. Hershey, Pennsylvania
  82. Hershey, Pennsylvania
  83. Charleston, South Carolina
  84. Charleston, South Carolina
  85. Dallas, Texas
  86. Dallas, Texas
  87. Dallas, Texas
  88. Dallas, Texas
  89. Dallas, Texas
  90. Dallas, Texas
  91. Houston, Texas
  92. Salt Lake City, Utah
  93. Seattle, Washington
  94. Seattle, Washington
  95. Morgantown, West Virginia
  96. Morgantown, West Virginia
  97. Cordoba,
  98. Adelaide, South Australia
  99. Box Hill, Victoria
  100. Toronto, Ontario
  101. Guangzhou, Guangdong
  102. Zhengzhou, Henan
  103. Changchun, Jilin
  104. Beijing,
  105. Beijing,
  106. Beijing,
  107. Tianjin,
  108. Brno,
  109. Hradec Kralove,
  110. Praha 10,
  111. Helsinki,
  112. Helsinki,
  113. Dijon,
  114. Grenoble Cedex 09,
  115. Le Chesnay Cedex,
  116. Limoges Cedex,
  117. Marseille,
  118. Paris Cedex 10,
  119. Pierre Benite Cedex,
  120. Saint Priest en Jarez Cedex,
  121. Toulouse Cedex 9,
  122. Vandoeuvre-les-Nancy,
  123. Muenster, Nordrhein-westfalen
  124. Frankfurt,
  125. Heidelberg,
  126. Köln,
  127. Muenchen,
  128. Muenster,
  129. Muenster,
  130. Budapest,
  131. Debrecen,
  132. Cagliari, CA
  133. Cagliari, CA
  134. Cagliari, CA
  135. Meldola (FC), FC
  136. Bologna,
  137. Catania,
  138. Catania,
  139. Cona, Ferrara,
  140. Genova,
  141. Genova,
  142. Genova,
  143. Genova,
  144. Genova,
  145. Milano,
  146. Milano,
  147. Milano,
  148. Monza,
  149. Monza,
  150. Napoli,
  151. Napoli,
  152. Pavia,
  153. Ravenna,
  154. Ravenna,
  155. Ravenna,
  156. Udine,
  157. Udine,
  158. Nagoya, Aichi
  159. Nishinomiya-shi, Hyogo
  160. Sendai, Miyagi
  161. Osaka-city, Osaka
  162. Chuo-ku, Tokyo
  163. Akita,
  164. Fukuoka,
  165. Kanagawa,
  166. Hwasun-Gun, Jeonnam
  167. Seoul,
  168. Seoul,
  169. Rotterdam, South Holland
  170. Rotterdam, South Holland
  171. Gdansk,
  172. Lodz,
  173. Warsaw,
  174. Wroclaw,
  175. Singapore,
  176. Singapore,
  177. Badalona, Barcelona
  178. Salamanca, Castille AND LION
  179. Barcelona, Catalonia
  180. Palma de Mallorca, Mallorca
  181. Barcelona,
  182. Madrid,
  183. Madrid,
  184. Madrid,
  185. Murcia,
  186. Sevilla,
  187. Valencia,
  188. Lund,
  189. Stockholm,
  190. Kaohsiung,
  191. Taipei,
  192. Southampton, Hampshire
  193. Bristol,
  194. Hull,
  195. London,
  196. Manchester,
  197. Nottingham,
  198. Oxford,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Treatment Study Protocol for Participants 1-45 Years With Acute Lymphoblastic Leukaemia
Official Title  ICMJE ALLTogether1 - A Treatment Study Protocol of the ALLTogether Consortium for Children and Young Adults (1-45 Years of Age) With Newly Diagnosed Acute Lymphoblastic Leukaemia (ALL)
Brief Summary ALLTogether collects the experience of previously successful treatment of children and young adults, with ALL from a number of well-renowned study groups into a new master protocol, which is both a comprehensive system for stratification and treatment of ALL in this age-group as well as the basis for several randomised and interventional trials included in the study-design.
Detailed Description

ALLTogether is a European clinical treatment study for acute lymphoblastic leukaemia (ALL) in children and young adults. The aims are to improve survival and quality of survival for children and young adults with ALL. In young people, ALL has excellent outcome with an overall survival of about 92% in children and 75% in young adults. However, patients still die of disease - from relapse because of under-treatment and a large fraction of patients are also over-treated: All patients risk treatment-related death and some suffer long-term side-effects or secondary cancer. To show improvement with such good survival, large populations are needed.

Study groups from Sweden, Norway, Iceland, Denmark, Finland, Estonia and Lithuania (NOPHO), the UK (UKALL), the Netherlands (DCOG), Germany (COALL), Belgium (BSPHO), Portugal (SHOP), Ireland (PHOAI), and France (SFCE), have designed a common treatment protocol for children and young adults with ALL.

The study has a complex clinical trial design with sub-protocols (the randomisations / intervention) connected to a master protocol. The master protocol consists of well established therapy-elements and in its design typical for current ALL therapy. The master protocol therapy is in the study design considered as standard of care (SOC) therapy for children and young adults with ALL.

The study structure is defined by a master protocol onto which randomised and interventional sub-protocols as well as sub-studies may be added, run and stop in a modular fashion.

The randomisations / intervention may identify therapy that is less toxic, but equally efficacious for sub-groups of patients and innovative therapy that may reduce relapses and death from ALL. In the master protocol, improved risk-stratification is likely to increase survival and reduce unnecessary toxicity and the introduction of therapeutic drug monitoring (TDM) of Asparaginase activity will make the use of Asparaginase more rational and efficient and may thus improve overall outcomes.

The investigators hypothesise that patients stratified to the standard-risk group are over-treated. Therefore, it will be tested if the treatment can be safely reduced. In the R1 randomisation, patients will be randomised to receiving the Delayed Intensification (DI) phase of therapy with or without the anthracycline Doxorubicin.

A similar hypothesis of over-treatment will also be tested in patients stratified to the intermediate risk-low group. In the R2 randomisation patients will be randomly assigned to either removal of Doxorubicin during the DI phase or removal of Vincristine and Dexamethasone pulses during the maintenance phase or to the control group, which will be treated with Doxorubicin in DI as well as Vincristine and Dexamethasone pulses during maintenance. Patients will only be randomised once.

Randomisation R1 and R2 are only considered for children since adults have worse outcome and very poor survival after relapse, but the risk-stratification is likely to reduce the number of high-risk cases also in the adult-group.

Patients stratified as intermediate risk-high (IR-high) are identified as having an increased risk of relapse and thus a less favourable prognosis than the standard- and intermediate risk-low groups, but a more favourable prognosis than the high risk patients. The majority of all relapses in childhood ALL occur in the IR-high group. Following a relapse, 40 % of the children can be successfully treated again and for adults the corresponding figure is less than 20 %, so preventing relapses is very important. New treatment options that improves the antileukemic efficacy and which have an improved safety profile are urgently needed.

For IR-high patients the R3 randomisation is available. In R3 patients will be randomised to the addition of two cycles of Inotuzumab ozogamicin (InO) - Besponsa®, before the start of the maintenance phase or no addition. The patients randomised to the InO arm will receive maintenance for the same duration as in the control arm.

Patients with ABL-class fusions in their leukaemic clone will, as a non-randomised experimental intervention, be treated with an addition of a tyrosine-kinase inhibitor during the induction phase (for patients <25 years) and from the consolidation phase (patients ?25 years). This intervention may shift therapy for previously resistant cases to lower intensity treatment with the associated reduced morbidity and may also reduce the number of relapses in analogy with the results in Ph+ ALL. The reason for not performing a randomised comparison is the rarity of the aberration and also the diversity of ABL-class fusions, reducing statistical power for any comparison further. For this reason, the results of this intervention may be pooled with other study-groups trying similar approaches.

For high-risk B-lineage patients, CAR-T therapy can be an alternative to high-risk blocks and stem-cell transplant, but in this case the intervention (CAR-T infusion) will be performed outside the ALLTogether1 study. However, the stratification-system in ALLTogether1 will define the population with a potential CAR-T indication.

ALLTogether1 also includes five sub-studies:

Efficacy of Imatinib in ABL-class fusion positive ALL

Target population: All ABL-class patients enrolled in the ALLTogether study. Biomaterials to be collected at diagnosis, follow-up and relapse.

Aims

  1. To determine the efficacy of imatinib in the treatment of ABL-class leukemia
  2. To find the best discriminative biomarkers for TKI response in ABL-class ALL
  3. To determine the frequency of intrinsic (at diagnosis) and acquired TKI resistance (due to treatment)
  4. To find causes of TKI resistance in ABL-class patients

Objectives

  1. To determine the percent of ABL-class patients who need to switch from IR-high to HR because of high MRD levels
  2. To determine the effect of imatinib exposure on clinical outcome
  3. To determine the molecular response to imatinib by monitoring fusion transcript levels and mutational spectrum at diagnosis and during follow up
  4. To determine whether the molecular response parameters reflect the Ig/TCR MRD or flow-MRD response or are a better predictor of therapy failure than Ig/TCR or flow-based MRD monitoring
  5. To determine the phosphorylation status of ABL-class proteins and presence of TKI-resistance associated mutations in ABL genes prior to imatinib treatment and the emergence of such mutations during treatment with imatinib
  6. To determine the presence of mutations in regulatory /other genes before and during imatinib treatment and functionally address the importance of these mutations in TKI resistance
  7. To determine whether the efficacy of TKIs depends on the type of fusion gene

Biomarkers to Reform Approaches to therapy-Induced Neurotoxicity (BRAIN)

Target population: All patients registered on ALLTogether1 aged ? 4 years at end of therapy and without:

  1. Pre-existing neurodevelopmental disorder (e.g Trisomy 21, ADHD) prior to diagnosis of ALL
  2. Significant visual or motor impairment preventing use of a touch screen ipad

Aims

  1. To institute universal screening of all children for adverse neurocognitive outcomes at the end of treatment using a validated user-friendly computer software programme (CogState) and compare neurocognitive outcomes by treatment allocation.
  2. To identify risk factors for adverse outcomes including whether acute neurotoxic events are associated with poor performance on cognitive tests at end of therapy compared to patients without acute neurotoxicity.

Primary end-point

a. Proportion of children with a z-score <1.5 on detection and/or identification CogState tasks in each treatment arm at the end of anti-leukaemic therapy. A z-score < 1.5 correlates with moderate cognitive impairment at a level that may require additional support.

Secondary and exploratory end-points

  1. Association between CogState scores at end of treatment and overt neurotoxic episodes as recorded on the trial adverse event database.
  2. Association between Cogstate scores and clinical and demographic variables - age, sex, ethnicity, CNS status.
  3. Proportion of children with scores <1.5SD for one card learning (learning), one back (working memory) and Groton's maze (executive function) on different treatment arms.
  4. Association between CogState scores and patient reported outcome measures/Quality of life measurements collected as part of the main ALLTogether1 trial.

Association between asparaginase activity levels and outcome

Target population: All patients included in the ALLTogether1 protocol are eligible for participation.

Primary aim

To study the association between asparaginase activity levels and outcome (MRD, relapse, survival)

Secondary aims

  1. To evaluate the association between asparaginase activity levels and toxicities, such as pancreatitis, infections and deep venous thrombosis (DVT)
  2. To evaluate the association between asparaginase activity levels and hepatotoxicity in a subset of patients

CSF-Flow

Target population: All patients included in the ALLTogether1 protocol are eligible for participation

Aims

  1. To use cerebrospinal fluid (CSF) flow cytometry (FCM) to improve the accuracy of diagnostic tests for CNS leukaemia compared to conventional CSF cytology. An associated objective will be to develop a recommended protocol for CSF flow cytometry with external quality assessment to ensure uniformity of measurement across the ALLTogether consortium.
  2. To investigate whether negative FCM identifies a group of children at very low risk of CNS relapse, suitable for testing de-escalation of CNS-directed therapy in future trials.
  3. To investigate whether positive FCM can identify children at increased risk of CNS relapse and whether patients with persistent positivity (FCM positive at day 15 onwards) might benefit from studies testing escalated CNS-directed therapy or a switch to more intensive treatment arms.
  4. To collect matching CSF supernatant for studies comparing CSF FCM with soluble biomarkers (e.g. metabolic, cell-free DNA, proteomic and microRNA) in selected centres.

Maintenance therapy pharmacokinetics/-dynamics study

Target population: All patients included in the ALLTogether1 protocol are eligible for participation. For IR-high patients participating in the randomised InO- and TEAM sub-protocols, the monitoring of 6-mercaptopurine (6MP)/Methotrexate (MTX) metabolites at three months intervals is mandatory.

Aims and specific objectives

  1. To map pharmacokinetics of 6MP and MTX during maintenance therapy in all patients in the ALLTogether protocol.
  2. To associate metabolite profiles with TPMT and NUDT15 variants, as routinely analysed in ALLTogether.
  3. To explore the association of event-free survival with DNA-TG and other 6MP/MTX metabolites.
  4. To explore the association between risk of second cancers with DNA-TG and other 6MP/MTX metabolites.
  5. To explore the association of risk of invasive infections with DNA-TG and other 6MP/MTX metabolites.
  6. To explore the association of risk of osteonecrosis with DNA-TG and other 6MP/MTX metabolites.
  7. To explore the association of sinusoidal obstruction syndrome with DNA-TG and other 6MP/MTX metabolites.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Sequential Assignment
Intervention Model Description:
Master protocol with risk-stratification. The risk-stratified groups will proceed to non-randomised or randomised interventions in single arm (TKI) and parallel (R1/R2/R3) models.
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Leukemia, Acute Lymphoblastic
Intervention  ICMJE
  • Drug: Omitted Doxorubicin
    Omission of IV Doxorubicin
  • Drug: Omitted Vincristine+Dexamethasone pulses
    Omission of Vincristine+Dexamethasone pulses
  • Drug: Inotuzumab Ozogamicin+Standard Maintenance Therapy
    Addition of IV Inotuzumab ozogamicin before Maintenance Therapy
    Other Name: Besponsa+Maintenance Therapy
  • Drug: Imatinib
    p.o. Imatinib
Study Arms  ICMJE
  • No Intervention: R1 - SR standard arm
    Standard risk arm receiving standard treatment (Delayed Intensification including Doxorubicin).
  • Experimental: R1 - SR experimental arm
    Standard risk arm, receiving Delayed Intensification without Doxorubicin IV 3 x 30 mg/m2/dose.
    Intervention: Drug: Omitted Doxorubicin
  • No Intervention: R2 - IR-low standard arm
    Standard treatment with Delayed Intensification including Doxorubicin and Maintenance including Vincristine+Dexamethasone pulses.
  • Experimental: R2 - IR-low experimental arm
    Standard treatment with omission of either (2 experimental arms) Doxorubicin IV 3 x 30 mg/m2/dose in the Delayed Intensification phase OR Monthly pulses of Vincristine IV 1,5 mg/m2/dose and 5 days of Dexamethasone p.o. 6 mg/m2/day in the Maintenance Phase.
    Interventions:
    • Drug: Omitted Doxorubicin
    • Drug: Omitted Vincristine+Dexamethasone pulses
  • No Intervention: R3 - IR-high standard arm
    Intermediate risk high arm receiving Standard Maintenance Therapy.
  • Experimental: R3 - IR-high experimental arm
    Inotuzumab IV 0,5 mg/m2, given on days 253, 260, 267 and on days 274, 281, 288 before start of Standard Maintenance Therapy.
    Intervention: Drug: Inotuzumab Ozogamicin+Standard Maintenance Therapy
  • Experimental: ABL-class fusions intervention
    Imatinib p.o. 340 mg/m2 given daily from day 15 or 30 (depending on age) to the end of therapy (week 106) in addition to standard IR-high chemotherapy.
    Intervention: Drug: Imatinib
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: March 12, 2020)
6430
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE June 30, 2032
Estimated Primary Completion Date June 30, 2027   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Patients newly diagnosed with T-lymphoblastic (T-cell) or B-lymphoblastic precursor (BCP) leukaemia (ALL) according to the WHO-classification of Tumours of Haematopoetic and Lymphoid Tissues (Revised 4th edition 2017) and with a diagnosis confirmed by an accredited laboratory at a participating paediatric oncology or adult haematology centre.
  • Age ? 365 days and < 46 years (one day before 46th birthday) at the time of diagnosis.
  • Informed consent signed by the patient and/or parents/legal guardians according to country-specific age-related guidelines (http://www.ema.europa.eu/docs/en_GB/document_library/Other/2015/12/WC50… ).
  • The ALL diagnosis should be confirmed by an accredited laboratory at a participating paediatric oncology or adult haematology centre.
  • The patient should be diagnosed and treated at a participating paediatric oncology or adult haematology centre in the participating countries.
  • The patient should be a resident in one of the participating countries on a permanent basis or should intend to settle in a participating country, for instance by an application for asylum. Patients who are visiting the country as tourists should not be included. However, returning expatriots with primary diagnosis abroad may be included if no treatment has been administered and the diagnostic procedures are repeated at a participating centre.
  • All women of childbearing potential (WOCBP) have to have a negative pregnancy test within 2 weeks prior to the start of treatment.
  • For each intervention/randomisation an additional set of inclusion-criteria is provided.

Exclusion Criteria:

  • Age < 365 days at diagnosis (infant ALL) or >45 years at diagnosis.
  • Patients with a previous malignant diagnosis (ALL as a second malignant neoplasm - SMN).
  • Relapse of ALL.
  • Patients with mature B-ALL (as defined by Surface Ig positivity or documented presence of one of the t(8;14), t(2;8), t(8;22) translocations and breakpoint as in B-ALL).
  • Patients with Ph-positive ALL (documented presence of t(9;22)(q34;q11) and/or of the BCR/ABL fusion transcript). These patients will be transferred to an adequate trial for t(9;22) if available.
  • ALL prone syndromes (e.g. Li-Fraumeni syndrome, germline ETV6 mutation), except for Down syndrome. Exploration for such ALL prone syndromes is not mandatory.
  • Treatment with systemic corticosteroids (>10mg/m2/day) for more than one week and/or other chemotherapeutic agents in a 4-week interval prior to diagnosis (pre-treatment).
  • Pre-existing contraindications to any treatment according to the ALLTogether protocol (constitutional or acquired disease prior to the diagnosis of ALL preventing adequate treatment).
  • Any other disease or condition, as determined by the investigator, which could interfere with the participation in the study according to the study protocol, or with the ability of the patients to cooperate and comply with the study procedures.
  • Women of childbearing potential who are pregnant at the time of diagnosis.
  • Women of childbearing potential and fertile men who are sexually active and are unwilling to use adequate contraception during therapy. Efficient birth control is required.
  • Female patients, who are breast-feeding.
  • Essential data missing from the registration of characteristics at diagnosis (in consultation with the protocol chair).
  • For each intervention/randomisation an additional set of exclusion-criteria is provided.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 1 Year to 45 Years   (Child, Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Global Clinical Trial Manager ALLTogether1+46 8 524 800 00[email protected]
Listed Location Countries  ICMJE Belgium,   Denmark,   Estonia,   Finland,   Germany,   Iceland,   Ireland,   Lithuania,   Netherlands,   Norway,   Portugal,   Sweden,   United Kingdom
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04307576
Other Study ID Numbers  ICMJE ALLTogether1
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
IPD Sharing Statement  ICMJE
Plan to Share IPD:Undecided
Plan Description:The trial steering committee has not yet had the opportunity to discuss and decide on a plan to share IPD. Since no publication will be forthcoming from the study within at least 5 years (currently 2025), this shortcoming will be amended within a year (before 2021).
Responsible Party Mats Heyman, Karolinska University Hospital
Study Sponsor  ICMJE Mats Heyman
Collaborators  ICMJE
  • The Swedish Research Council
  • The Swedish Childhood Cancer Foundation
  • Pfizer
  • Servier
  • NordForsk
  • Aamu Pediatric Cancer Foundation
  • Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany
  • Clinical Trial Center North (CTC North GmbH & Co. KG)
  • Belgium Health Care Knowledge Centre
  • Karolinska Institutet
  • Cancer Research UK
  • Fundação Rui Osório de Castro
  • Acreditar - Associação de Pais e Amigos das Crianças com Cancro
  • Grupo Português De Leucemias Pediátricas
Investigators  ICMJE
Study Chair:Mats Heyman, MD, PhDKarolinska University Hospital
PRS Account Karolinska University Hospital
Verification Date October 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP